DJIA 17,730.11 0.00 0.00%
NASDAQ 5,009.21 0.00 0.00%
S&P 500 2,076.78 0.00 0.00%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

company name or ticker

Sarepta Explodes On Monster Volume Following Progress With FDA

Wednesday Sector Leaders: Biotechnology, Television & Radio Stocks

Why Shares of Sarepta Therapeutics Skyrocketed Today

Shares of the clinical-stage biotech Sarepta Therapeutics bolted higher by over 50% today. Here's why.

Sarepta Therapeutics (SRPT) Stock Soars Following Positive Meeting With FDA

How Sarepta Short Interest Is Adding to Its Gains

Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying

Why I'm Buying Sarepta Therapeutics Stock

Sarepta Therapeutics got some great news from the FDA yesterday that sent shares soaring. Here's why the stock is definitely worth a deeper dive by risk-tolerant investors.

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

Forget Gilead Sciences, Inc. -- This Tiny Biotech Offers A Much Richer Opportunity

Sarepta Therapeutics is nearing the moment of truth for its Duchenne muscular dystrophy treatment eteplirsen. If all goes according to plan, this single drug could transform this tiny biotech into one of the best performing healthcare stocks in 2015. Here's why.

Sarepta Posts Wider-than-Expected Loss, Eteplirsen in Focus - Analyst Blog

See More Articles...